Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation
Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation
复制标题
癌症治疗相关的心血管功能障碍：基本机制和临床表现
DOI：
10.1016/j.jjcc.2022.04.006
复制
发表时间：
2023
影响因子：
2.5
通讯作者：
Yasuchika Takeishi
中科院分区：
文献类型：
--
作者：
Masayoshi Oikawa;Takafumi Ishida;Yasuchika Takeishi
尽管癌症治疗的最新进展改善了癌症预后，但癌症治疗相关心血管功能障碍（CTRCD）显著增加了全球心血管疾病负担。CTRCD引起两个关键问题：一是化疗过早中断或终止；第二，在癌症治疗期间和之后发生充血性心力衰竭。因此，早期发现和及时治疗CTRCD可以改善肿瘤患者的预后。本文综述了具有代表性的抗癌药物，包括蒽环类药物、人表皮生长因子2抑制剂、酪氨酸激酶抑制剂、蛋白酶体抑制剂和免疫检查点抑制剂。我们关注CTRCD的分子机制和各种诊断、预防、监测和治疗方法。
Although recent advances in cancer treatment improve cancer prognosis, cancer therapeutics-related cardiovascular dysfunction (CTRCD) significantly contributes to the global burden of cardiovascular disease. CTRCD causes two crucial issues: first, premature treatment interruption or discontinuation of chemotherapy; second, the development of congestive heart failure during and after cancer treatment. Thus, early detection and prompt treatment of CTRCD may improve the prognosis in cancer patients. This review covers representative anticancer drugs, including anthracyclines, human epidermal growth factor 2 inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, and immune checkpoint inhibitors. We focus on the molecular mechanisms of CTRCD and various approaches to diagnosis, prevention, monitoring, and treatment.